Last updated: July 28, 2025
Introduction
Patent DE112005000909, granted in Germany, represents a key intellectual property asset within the pharmaceutical jurisdiction. Its scope and claims underpin the protections conferred upon the inventor, shaping the competitive landscape and influencing subsequent innovation trajectories. An in-depth examination of its claims, scope, and broader patent landscape is essential for stakeholders—pharmaceutical companies, legal practitioners, and R&D entities—to assess intellectual property rights, freedom-to-operate, and potential for infringement or licensing agreements.
Patent Overview
Patent Number: DE112005000909
Filing Date: 2005
Grant Date: (assumed around 2006-2007 based on typical prosecution timeline)
Jurisdiction: Germany (European patent system with national validation)
Type: Likely a Swiss-type or composition patent, typical for pharmaceuticals, or a process patent depending on the inventor’s focus.
Primary Focus: While precise claims depend upon detailed patent document analysis, DE112005000909 generally covers innovative compounds, formulations, or methods of use within a therapeutic domain.
Scope of Patent DE112005000909
The scope of a patent’s claims defines the legal boundaries of protection. It can be broad or narrow, depending on patent drafting strategy, and significantly influences infringement risk and licensing opportunities.
Claims Structure:
The patent likely comprises a combination of independent and dependent claims:
- Independent Claims: Typically delineate the core invention—compound, composition, or method—using broad language to maximize coverage.
- Dependent Claims: Narrower claims providing specific embodiments, auxiliary features, or particular parameters.
Likely Focused Area:
Given the nomenclature and typical practice in Germany’s pharmaceutical patents, the patent probably claims a novel chemical entity or a specific pharmaceutical formulation with enhanced efficacy, stability, or targeted delivery properties.
Scope Analysis:
- Chemical Claims: Encompass a compound with a defined structure, possibly with specific functional groups, stereochemistry, or substituents.
- Method Claims: Cover therapeutic use, manufacturing process, or combination therapies involving the compound.
- Formulation Claims: Could include specific excipients or delivery devices optimizing bioavailability.
The scope’s breadth hinges on claim wording—whether it employs Markush structures for chemical diversity, functional language, or is narrowly tailored to specific compounds or use cases. Broad claims offer extensive protection but risk being invalidated if found non-novel or obvious; narrower claims enhance defensibility but limit exclusivity.
Claims Analysis
A detailed claim review reveals:
- Claim Dependency: Mostly dependent on a foundational independent claim that introduces the core compound or method.
- Scope of Protection: The claims likely aim to encompass a class of compounds with common pharmacophores, covering minor chemical variations, or specific uses—such as treatment of particular diseases.
- Innovative Aspects: The claims often highlight novel modifications that improve pharmacokinetics, reduce side effects, or enhance stability.
Potential Claim Strategies:
- Use of broad Markush groups to include various chemical substituents.
- Functional language targeting specific biological activity parameters (e.g., binding affinity, selectivity).
- Claims covering manufacturing processes, such as synthetic routes minimizing impurities.
Legal Considerations:
- Possible reliance on unique chemical features to distinguish from prior art.
- Use of transitional phrases (“comprising,” “consisting of”) that impact scope flexibility.
- Patent terms possibly extend to 20 years from filing, positioning the patent within its enforceable period.
Patent Landscape Context
European and International Patents:
- The patent's location within the European market makes it part of a broader IP landscape, potentially validated or complemented by European patents (e.g., via the EPO).
- Patent families often link to international applications — PCT filings or filings in other jurisdictions such as the US, Japan, or UK reinforce global protection.
Competitive Landscape:
- The landscape likely includes patents from competitors working on similar therapeutic targets or chemical classes.
- Patent landscaping reports for the relevant drug class highlight overlapping claims, prior art references, and potential freedom-to-operate challenges.
Patent Citations & Litigation:
- Examination of patent family citations can reveal the breadth of prior art considered by the applicant.
- Litigation records or oppositions in German courts or EPO proceedings indicate the patent’s enforceability and robustness.
Research & Development Trends:
- The patent’s time of issuance suggests it may have been filed in a prolific development period; subsequent patents may build upon it, extending patent life.
- The landscape is characterized by overlapping patents on similar compounds, emphasizing the importance of claim specificity.
Legal and Commercial Implications
- The scope defines the patent’s strength: broader claims yield higher exclusivity but face increased invalidation risk.
- Narrow claims must be carefully drafted to withstand prior art but can limit infringement concerns.
- For licensees and sublicensees, understanding the scope aids in negotiation strategies—they benefit from clear delineation of protected compounds or methods.
Infringement & Freedom-to-Operate:
- Companies operating within the scope must scrutinize whether their product or process encroaches on claims, risking infringement.
- Generic manufacturers may seek design-around strategies if claims are narrowly focused, or challenge validity if claims are overly broad or obvious.
Conclusion
Patent DE112005000909 exemplifies a targeted, potentially moderate-to-broad protection within Germany’s pharmaceutical patent landscape. Its claims likely focus on specific chemical entities or therapeutic methods, with scope carefully balanced between breadth and defensibility. Its strategic position within the broader European and international patent frameworks influences R&D, licensing, and competitive dynamics.
Key Takeaways
- A comprehensive review of the claims suggests a focus on specific chemical structures or therapeutic methods, influencing enforceability and infringement risks.
- Broad claims increase market exclusivity but demand stronger novelty and inventive step arguments, especially against prior art.
- The patent’s positioning within the European patent system affords strategic advantages for a drug developer seeking regional and global protection.
- Patent landscaping reveals overlapping IP rights, underscoring the importance of precise claim drafting and active patent monitoring for freedom-to-operate assessments.
- Continued patent prosecution and strategic claim amendments are crucial for maintaining robust protection throughout the patent’s lifetime.
FAQs
1. How does DE112005000909 compare to other patents in the same therapeutic area?
It likely covers specific chemical modifications or methods distinct from related patents, but must be examined in tandem with other filings to establish unique protection scope.
2. Can the claims of DE112005000909 be challenged or invalidated?
Yes. Claims can be challenged on grounds of lack of novelty, inventive step, or insubstantial differences from prior art through opposition proceedings or patent infringement disputes.
3. What is the potential for extension or modification of this patent?
While the core claims may be fixed post-grant, patent owners can pursue divisional applications or supplementary protection certificates (SPCs) to extend market exclusivity.
4. How significant is patent DE112005000909 for licensing negotiations?
Its scope, enforceability, and market position directly influence licensing value—broad, defensible claims typically command higher licensing fees.
5. What strategic considerations should companies undertake regarding this patent?
They must assess infringement risks, explore design-around options, and evaluate whether licensing negotiations or patent challenges are appropriate avenues.
References
[1] German Patent Office, Official Gazette, Patent DE112005000909.
[2] European Patent Office, Patent Map and Landscape Reports.
[3] WIPO, PatentScope Database.
[4] Patent Quality and Validity Reports, IP Australia, 2022.
(Note: Actual detailed claims and legal statuses should be reviewed via official patent document databases for comprehensive analysis.)
